Scientists find the switch that lets lungs heal themselves

Your lungs have a built-in repair crew, but they've been working with the brakes on. Researchers at Mayo Clinic have just figured out which molecular switch controls whether lung cells focus on healing damage or fighting infection — a discovery that could reshape how we treat chronic lung diseases like pulmonary fibrosis.

The story centers on alveolar type 2 cells, or AT2 cells. These are the lung's unsung workers: they maintain the air sacs by producing proteins that keep them inflated with each breath, and they double as reserve stem cells ready to replace damaged tissue. The problem is that in adult lungs, these cells get locked into a rigid, specialized state. They forget how to regenerate.

The Molecular Clamp

Using single-cell sequencing and imaging, the Mayo team traced the life cycle of AT2 cells and discovered something crucial. For about one to two weeks after birth, these cells stay flexible and adaptable. Then something clicks. Three molecular regulators — PRC2, C/EBPα, and DLK1 — work together to settle the cells into permanent specialization. Think of C/EBPα as a clamp that locks down stem cell behavior.

Here's where it gets interesting: when an adult lung gets injured, AT2 cells need to release that clamp to start healing. But the same mechanism also determines whether they prioritize repair or immune defense. This explains why infections can derail recovery in people with chronic lung disease — the cells get caught between two jobs.

"When we think about lung repair, it's not just about turning things on — it's about removing the clamps that normally keep these cells from acting like stem cells," says Dr. Brownfield, who led the research. "We discovered one of those clamps and how it times the ability of these cells to repair."

What This Means Next

The implications are concrete. Treatments designed to adjust C/EBPα activity could potentially enhance AT2 cells' ability to rebuild scarred lung tissue or slow the progression of pulmonary fibrosis. The research also opens a door to earlier diagnosis: clinicians might eventually recognize when AT2 cells are locked down and unable to regenerate, creating new biomarkers for lung disease.

Mayo researchers are now testing whether they can remove the restrictive clamp from human AT2 cells grown in the lab, exploring whether these reactivated cells could eventually be used in cell replacement therapies. The work won't solve lung disease overnight, but it shifts the conversation from "we can only slow this down" to "we might be able to restart the body's own repair system."

The study appears in Nature Communications, 2025.